Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapsone + tretinoin is a combination of two pharmaceutical agents commonly used in dermatology, particularly for the treatment of acne vulgaris. Dapsone is a sulfone antibiotic and anti-inflammatory agent that inhibits dihydropteroate synthase, blocking folic acid synthesis in bacteria and reducing neutrophil-mediated inflammation. Tretinoin is a retinoid that acts as an agonist at retinoic acid receptors (RARs), modulating gene expression to promote cell differentiation and reduce keratinocyte proliferation. The combination leverages both antibacterial/anti-inflammatory effects (from dapsone) and normalization of skin cell turnover (from tretinoin), making it effective for inflammatory acne lesions[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dapsone + tretinoin.